South Korea-based company, which develops and distributes MRI (Feridex I.V.) and X-ray contrast media.

MRI Contrast Agents:

The Esaote Group, founded in the 1980's, is a global leader in research, production, and marketing of medical diagnostic equipment and related services. Esaote offers integrated diagnostic solutions for ultrasound electromedical diagnostic systems, and MRI. The Esaote MR equipment is dedicated for specific clinical applications, as distinguished from conventional whole body MRI systems. This MRI product family is based on a unique, proprietary technology developed specifically for musculoskeletal imaging.
The Italian based company is a member of the Bracco Group.
Esaote North America is the exclusive U.S. distributor of MRI devices manufactured by Esaote.

MRI Scanners:

0.2T to 0.31T:
Vet-MR (Based on the E Scan XQ, dedicated to the veterinarian practice.)

USA-based, privately hold, headquartered in Palo Alto and Beijing is the company bridging the traditional medical practices of Asia with advances in modern pharmaceuticals.

MRI Contrast Agents:

[This entry is marked for removal.]

Cytogen Corporation of Princeton, NJ is a product-driven, oncology-focused biopharmaceutical company. Cytogen markets several products through its in- house oncology sales force: ProstaScint® (a monoclonal antibody-based imaging agent used to image the extent and spread of prostate cancer); BrachySeed™ I-125 and BrachySeed™ Pd-103 (two uniquely designed, next generation radioactive seed implants for the treatment of localized prostate cancer), and NMP22® BladderChek™ (a highly accurate and convenient antibody-based point-of-care staging test for bladder cancer detection). Cytogen has also developed Quadramet®, a skeletal targeting therapeutic radiopharmaceutical for the relief of bone pain in prostate and other types of cancer. Cytogen's pipeline comprises product candidates at various stages of clinical development, including fully human monoclonal antibodies and cancer vaccines based on PSMA (prostate specific membrane antigen) technology, which was exclusively licensed from Memorial Sloan-Kettering Cancer Center.
A license and marketing agreement with AMAG Pharmaceuticals Inc' (formerly Advanced Magnetics), to market the functional molecular imaging agent Combidex®, was terminated in 2007.

[This entry is marked for removal.]

E-Z-EM, Inc. is headquartered in New York and develops, manufactures and markets diagnostic imaging products used by radiologists like the MRI bowel marker Gadolite® Oral Suspension.
In addition to medical diagnostics systems, the company's products include MR-compatible interventional devices, such as biopsy needles. E-Z-EM is also a third-party contract manufacturer of contrast media.
Bracco Diagnostics, Inc. , the US-based subsidiary of Bracco Imaging S.p.A. and part of the Bracco Group, announced in Oct. 2007 that it has entered into a merger agreement to acquire E-Z-EM, Inc. (NASDAQ: EZEM) for a total consideration of about $ 240 million. Upon completion of the procedure and subject to the approval of the regulatory authorities, Bracco Diagnostics Inc. will incorporate E-Z-EM.